Product loss mitigation through drying technology

By Maggie Lynch

- Last updated on GMT

(Image: Getty/	Oleh_Kucheriavyi)
(Image: Getty/ Oleh_Kucheriavyi)
Small molecule manufacturing can result in product loss, as the materials manufactured come into contact with internal surfaces thereby impacting drying and creating disruptions in efficency and cost-effectivness.

We spoke with Ryan Murphy, senior VP sales and marketing at Marion Process Solutions, who will be representing the manufacturing solutions company at Interphex next week, regarding the impact of product loss on the pharmaceutical industry and mitigation techniques.

Murphy told us, “Most commonly we hear from customers that product loss is directly attributable to caking of product on internal contact surfaces, equipment operator errors or equipment not functioning per specification.”

He continued that with this concern for product loss, processing repeatability has become a solution and enables manufacturers to decrease downtime related to cleanability.

Marion Process Solutions will be presenting its newest piece of equipment to meet repeatability. According to the company, its WaveMix technology can mitigate product loss and decrease downtime as it provides “extremely tight process control parameters.”

Mitigation of product loss, according to Murphy, can be achieved by limiting or eliminating material build-up on contact surfaces. This build-up is commonly seen in traditional drying technologies.

Murphy further stated that Marion Process’ WaveMix technology uses combination microwave, vacuum, and mixing to decrease product loss and results in a higher overall yield.   

Related news

Show more

Related products

show more

Solution for challenging antibodies – Planova™ S20N

Solution for challenging antibodies – Planova™ S20N

Content provided by Asahi Kasei Medical Co., Ltd. | 24-Sep-2024 | White Paper

Designed as a next generation cellulose-based virus removal filter, Planova™ S20N has demonstrated robust filtration performance for challenging molecules...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Follow us

Products

View more

Webinars